Evidence map›Paper›PMID 36145632›Full record

ReviewPharmaceutics2022

Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles.

Sakshi V Khairnar, Pritha Pagare, Aditya Thakre, Aswathy Rajeevan Nambiar, Vijayabhaskarreddy Junnuthula, Manju Cheripelil Abraham, Praveen Kolimi, Dinesh Nyavanandi, Sathish Dyawanapelly

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 219 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Sakshi V KhairnarDepartment of Pharmaceutical Science and Technology, Institute of Chemical Technology, Mumbai 400019, India.
Pritha PagareDepartment of Pharmaceutical Science and Technology, Institute of Chemical Technology, Mumbai 400019, India.
Aditya ThakreDepartment of Pharmaceutical Science and Technology, Institute of Chemical Technology, Mumbai 400019, India.
Aswathy Rajeevan NambiarIndependent Researcher, 4/2 Moore Street, Gwynneville, Wollongong, NSW 2500, Australia.
Vijayabhaskarreddy JunnuthulaDrug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00790 Helsinki, Finland.
Manju Cheripelil AbrahamDepartment of Engineering Mathematics, University of Bristol, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, UK.
Praveen KolimiDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, MS 38677, USA.
Dinesh NyavanandiPharmaceutical Development Services, Thermo Fisher Scientific, Cincinnati, OH 45237, USA.
Sathish DyawanapellyDepartment of Pharmaceutical Science and Technology, Institute of Chemical Technology, Mumbai 400019, India.ORCID 0000-0002-2310-1651
Institute of Chemical Technology · INThermo Fisher Scientific (United States) · USUniversity of Bristol · GBUniversity of Helsinki · FIUniversity of Mississippi · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid lipid nanoparticles (SLNs) are an alternate carrier system to liposomes, polymeric nanoparticles, and inorganic carriers. SLNs have attracted increasing attention in recent years for delivering drugs, nucleic acids, proteins, peptides, nutraceuticals, and cosmetics. These nanocarriers have attracted industrial attention due to their ease of preparation, physicochemical stability, and scalability. These characteristics make SLNs attractive for manufacture on a large scale. Currently, several products with SLNs are in clinical trials, and there is a high possibility that SLN carriers will quickly increase their presence in the market. A large-scale manufacturing unit is required for commercial applications to prepare enough formulations for clinical studies. Furthermore, continuous processing is becoming more popular in the pharmaceutical sector to reduce product batch-to-batch differences. This review paper discusses some conventional methods and the rationale for large-scale production. It further covers recent progress in scale-up methods for the synthesis of SLNs, including high-pressure homogenization (HPH), hot melt extrusion coupled with HPH, microchannels, nanoprecipitation using static mixers, and microemulsion-based methods. These scale-up technologies enable the possibility of commercialization of SLNs. Furthermore, ongoing studies indicate that these technologies will eventually reach the pharmaceutical market.

Indexed as

drug deliveryhigh-pressure homogenizationnanomedicinesscale-upsolid lipid nanoparticles

Identifiers

PMID36145632
PMCPMC9503303
OpenAlexW4296806810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.